AP -- Losses are narrowing at Elan Corp. PLC as sales of its key drug, the multiple sclerosis-fighting Tysabri, keep growing in the United States and Europe, the Irish biopharmaceutical company reported Tuesday.
AP -- Losses are narrowing at Elan Corp. PLC as sales of its key drug, the multiple sclerosis-fighting Tysabri, keep growing in the United States and Europe, the Irish biopharmaceutical company reported Tuesday.
